Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020

被引：24

作者：

Chen, Roufen ^{[1
]}

Gao, Yali ^{[2
]}

Liu, Han ^{[1
]}

Li, He ^{[1
]}

Chen, Wenfa ^{[2
]}

Ma, Junjie ^{[1
]}

机构：

[1] Huaqiao Univ, Sch Med, Quanzhou 362000, Peoples R China

[2] Fujian Med Univ, Pharm Dept, Affiliated Hosp 2, Quanzhou 362000, Peoples R China

来源：

RSC MEDICINAL CHEMISTRY | 2023年 / 14卷 / 01期

关键词：

RESPIRATORY SYNDROME-CORONAVIRUS; 3CL PROTEASE; ACTIVE-SITE; SARS; DISCOVERY; NITRILE;

D O I：

10.1039/d2md00344a

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

COVID-19 caused by SARS-CoV-2 in late 2019 is still threatening global human health. Although some vaccines and drugs are available in the market, controlling the spread of the SARS-CoV-2 virus remains a huge challenge. 3C-like protease (3CL(pro)) is a highly conserved key protease for SARS-CoV-2 replication, and no relevant homologous protein with a similar cleavage site to 3CL(pro) has been identified in humans, highlighting that development of 3CL(pro) inhibitors exhibits great promise for treatment of COVID-19. In this review, the authors describe the structure and function of 3CL(pro). To better understand the characteristics of SARS-CoV-2 3CL(pro) inhibitors, the SARS-CoV-2 3CL(pro) inhibitors reported since 2020 are classified into peptidomimetic covalent inhibitors, non-peptidomimetic covalent inhibitors and non-covalent small molecule inhibitors, and the representative inhibitors, their biological activities and binding models are highlighted. Collectively, we hope that all the information presented here will provide new insights into the design and development of more effective 3CL(pro) inhibitors against SARS-CoV-2 as novel anti-coronavirus drugs.

引用

页码：9 / 21

页数：13

共 77 条

[1] Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective [J].

Aljoundi, Aimen ;

Bjij, Imane ;

El Rashedy, Ahmed ;

Soliman, Mahmoud E. S. .

PROTEIN JOURNAL, 2020, 39 (02) :97-105

[2] Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors [J].

Amin, Sk. Abdul ;

Banerjee, Suvankar ;

Ghosh, Kalyan ;

Gayen, Shovanlal ;

Jha, Tarun .

BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 29

[3] Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs [J].

Anand, K ;

Ziebuhr, J ;

Wadhwani, P ;

Mesters, JR ;

Hilgenfeld, R .

SCIENCE, 2003, 300 (5626) :1763-1767

[4]

[Anonymous], 2020, WHO COVID 19 EXPL

[5] Structural insights into SARS-CoV-2 proteins [J].

Arya, Rimanshee ;

Kumari, Shweta ;

Pandey, Bharati ;

Mistry, Hiral ;

Bihani, Subhash C. ;

Das, Amit ;

Prashar, Vishal ;

Gupta, Gagan D. ;

Panicker, Lata ;

Kumar, Mukesh .

JOURNAL OF MOLECULAR BIOLOGY, 2021, 433 (02)

[6] Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability [J].

Bai, Bing ;

Belovodskiy, Alexandr ;

Hena, Mostofa ;

Kandadai, Appan Srinivas ;

Joyce, Michael A. ;

Saffran, Holly A. ;

Shields, Justin A. ;

Khan, Muhammad Bashir ;

Arutyunova, Elena ;

Lu, Jimmy ;

Bajwa, Sardeev K. ;

Hockman, Darren ;

Fischer, Conrad ;

Lamer, Tess ;

Vuong, Wayne ;

van Belkum, Marco J. ;

Gu, Zhengxian ;

Lin, Fusen ;

Du, Yanhua ;

Xu, Jia ;

Rahim, Mohammad ;

Young, Howard S. ;

Vederas, John C. ;

Tyrrell, D. Lorne ;

Lemieux, M. Joanne ;

Nieman, James A. .

JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (04) :2905-2925

[7] Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 [J].

Boras, Britton ;

Jones, Rhys M. ;

Anson, Brandon J. ;

Arenson, Dan ;

Aschenbrenner, Lisa ;

Bakowski, Malina A. ;

Beutler, Nathan ;

Binder, Joseph ;

Chen, Emily ;

Eng, Heather ;

Hammond, Holly ;

Hammond, Jennifer ;

Haupt, Robert E. ;

Hoffman, Robert ;

Kadar, Eugene P. ;

Kania, Rob ;

Kimoto, Emi ;

Kirkpatrick, Melanie G. ;

Lanyon, Lorraine ;

Lendy, Emma K. ;

Lillis, Jonathan R. ;

Logue, James ;

Luthra, Suman A. ;

Ma, Chunlong ;

Mason, Stephen W. ;

McGrath, Marisa E. ;

Noell, Stephen ;

Obach, R. Scott ;

O' Brien, Matthew N. ;

O'Connor, Rebecca ;

Ogilvie, Kevin ;

Owen, Dafydd ;

Pettersson, Martin ;

Reese, Matthew R. ;

Rogers, Thomas F. ;

Rosales, Romel ;

Rossulek, Michelle I. ;

Sathish, Jean G. ;

Shirai, Norimitsu ;

Steppan, Claire ;

Ticehurst, Martyn ;

Updyke, Lawrence W. ;

Weston, Stuart ;

Zhu, Yuao ;

White, Kris M. ;

Garcia-Sastre, Adolfo ;

Wang, Jun ;

Chatterjee, Arnab K. ;

Mesecar, Andrew D. ;

Frieman, Matthew B. .

NATURE COMMUNICATIONS, 2021, 12 (01)

[8] SARS-CoV-2: from its discovery to genome structure, transcription, and replication [J].

Brant, Ayslan Castro ;

Tian, Wei ;

Majerciak, Vladimir ;

Yang, Wei ;

Zheng, Zhi-Ming .

CELL AND BIOSCIENCE, 2021, 11 (01)

[9] Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases [J].

Brogi, Simone ;

Ibba, Roberta ;

Rossi, Sara ;

Butini, Stefania ;

Calderone, Vincenzo ;

Gemma, Sandra ;

Campiani, Giuseppe .

MOLECULES, 2022, 27 (08)

[10] Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease [J].

Chan, Jasper F. W. ;

Lau, Susanna K. P. ;

To, Kelvin K. W. ;

Cheng, Vincent C. C. ;

Woo, Patrick C. Y. ;

Yuen, Kwok-Yung .

CLINICAL MICROBIOLOGY REVIEWS, 2015, 28 (02) :465-522

← 1 2 3 4 5 6 7 8 →